The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial

Continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enhanced transmissibility, significant immune escape, and waning immunity call for booster vaccination. We evaluated the safety, immunogenicity, and efficacy of heterologous booster with a SARS-CoV-...

Full description

Bibliographic Details
Main Authors: Chunhua Zhou, Yuanzheng Qiu, Jianxin Wang, Xiang Zhong, Xiufang Zhu, Xiaojing Huang, Lan Yang, Qiaolei Ji, Feifei Zhou, Shunquan Wu, Mengjie Yang, Jing Zhang, Kaili Liu, Li Ji, Hanyu Yang, Chunlei Li, Yuanyuan Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Emerging Microbes and Infections
Subjects:
SARS-CoV-2
mRNA vaccine
heterologous boosting
safety
immunogenicity
efficacy
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2024.2320913

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2024.2320913

Similar Items